Literature DB >> 1348162

Prospective study of neuroleptic-induced dystonia in mania and schizophrenia.

R Khanna1, A Das, S S Damodaran.   

Abstract

OBJECTIVE: The authors' goal was to conduct a prospective study comparing the rate of occurrence of neuroleptic-induced dystonia in a group of consecutively admitted manic and schizophrenic patients receiving typical inpatient treatment from several clinicians.
METHOD: All patients met the following criteria: 1) male sex, 2) age between 17 and 45 years, 3) definite diagnosis of mania or schizophrenia according to Research Diagnostic Criteria, 4) no exposure to neuroleptics during the past month, 5) absence of past or family history of a neurodegenerative disorder with extrapyramidal symptoms. All treatment decisions were left to the treating clinicians. Fifty patients with mania and 33 with schizophrenia were included in the study. Most of these patients received high-potency neuroleptics, but the specific neuroleptic used varied in the two groups.
RESULTS: Twelve (24%) of the patients with mania and five (15%) of the patients with schizophrenia developed acute dystonia. Manic patients received significantly higher peak doses of neuroleptics during the risk period for dystonia. Stepwise multiple regression analysis revealed that the peak neuroleptic dose and age were most strongly related to the occurrence of dystonia.
CONCLUSIONS: This prospective study failed to support the retrospective finding of another study that acute dystonia occurred more often in manic patients than in patients with nonparanoid schizophrenia. The authors conclude that there is a need for carefully controlled prospective studies with larger groups of patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348162     DOI: 10.1176/ajp.149.4.511

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  7 in total

Review 1.  Acute dystonia induced by drug treatment.

Authors:  P N van Harten; H W Hoek; R S Kahn
Journal:  BMJ       Date:  1999-09-04

Review 2.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 3.  Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.

Authors:  Keming Gao; David E Kemp; Stephen J Ganocy; Prashant Gajwani; Guohua Xia; Joseph R Calabrese
Journal:  J Clin Psychopharmacol       Date:  2008-04       Impact factor: 3.153

4.  A comparative study of neuroleptic induced neurological side effects in schizophrenia and mood disorders.

Authors:  P N Kumar; T M Kumar
Journal:  Indian J Psychiatry       Date:  1997-04       Impact factor: 1.759

5.  A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation.

Authors:  Theodore D Satterthwaite; Daniel H Wolf; Robert A Rosenheck; Raquel E Gur; Stanley N Caroff
Journal:  J Clin Psychiatry       Date:  2008-12-02       Impact factor: 4.384

6.  Risperidone-Induced Acute Laryngeal Dystonia: A Case Report.

Authors:  Ghassan A Alkharboush; Majid A Alsalamah
Journal:  Am J Case Rep       Date:  2020-06-07

7.  Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate.

Authors:  Francois-Pierre Joubert; Bonginkosi Chiliza; Robin Emsley; Laila Asmal
Journal:  S Afr J Psychiatr       Date:  2021-01-11       Impact factor: 1.550

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.